SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Investors are closely watching the GTC 2026 keynote as CEO Jensen Huang highlights a massive long-term outlook for AI infrastructure, with revenue projections reaching at least $1 trillion by 2027. Despite the bullish infrastructure narrative and active product launches, the community remains divided and highly frustrated by erratic price swings, which many traders blame on aggressive algorithmic manipulation and retail option trapping.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as the community debates the implications of its newly announced Xeon 6 processors powering NVIDIA's DGX Rubin systems, sparking intense discussions about whether this signals a pivotal ecosystem partnership or if the stock is trapped in a volatile pump-and-dump cycle. While some traders are bullish on the company's long-term integration into AI infrastructure, others remain skeptical, pointing to the stock's tendency to fade gains and persistent technical pressure from short-sellers.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is currently capturing attention as traders debate the potential impact of the proposed CLARITY Act and its role in fostering institutional adoption despite ongoing price volatility. While some community members remain deeply skeptical of market manipulation and the project's long-term utility, others view current price movements as an accumulation opportunity driven by growing international integration and anticipation of future regulatory milestones.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

CytomX Therapeutics is experiencing high-volume momentum and significant volatility following a positive clinical data update for its late-line colorectal cancer program, Varseta-M. Investors are heavily focused on the stock's potential for near-term catalysts, with community sentiment split between enthusiasm for its pipeline progress and caution regarding potential future dilution or earnings-related volatility.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is gaining significant investor attention amid high volatility and intense community speculation regarding a potential buyout, which remains a primary talking point as traders debate the stock's valuation versus institutional short positions. Despite persistent skepticism about market manipulation, bullish sentiment is being fueled by strong revenue growth from its core rare-disease portfolio and anticipation surrounding upcoming data for its pipeline candidate, navenibart.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is surging after securing a massive five-year, $27 billion AI infrastructure deal with Meta, a move that reinforces its position as a top-tier provider for high-performance computing. Community sentiment is overwhelmingly bullish, with investors viewing the partnership and recent strategic backing from NVIDIA as proof that the company is effectively capturing long-term hyperscaler demand.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance is currently experiencing significant downward volatility and high trading volume as investors react to the unwinding of previous speculative momentum and broader concerns across the mortgage sector. While the community remains deeply divided, active discussions are focused on the company's long-term potential for AI-driven mortgage origination via its Tinman platform, with some investors accumulating positions at lower price points in anticipation of future partnership announcements and institutional scaling.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to the announcement that its commercially manufactured GP2 vials are now being used in the Phase III FLAMINGO-01 trial, a move that investors view as a key de-risking step toward potential commercialization. The community is heavily focused on the elite Steering Committee's co-authorship of upcoming AACR abstracts and the CEO's consistent open-market share accumulation, fueling speculation about a major breakthrough or acquisition.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

Geo Group is trending as investors weigh strong quarterly revenue and earnings beats against concerns about the pace of detention facility activations and potential political headwinds. The community is actively discussing the company's increased share buyback authorization while closely monitoring how DHS funding and potential policy shifts under the new administration will impact future contract opportunities.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is surging as investors react to a combination of its upcoming NYSE uplisting, a significant government defense contract award, and high-profile media appearances by CEO Gary Evans. The community is heavily focused on the company's potential to capitalize on the growing demand for critical minerals like antimony and tungsten amid ongoing supply chain concerns and geopolitical tensions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SRTS Why is this decline positive for the company’s future?

Because it reflects a strategic transition away from dependency on a single large buyer and toward diversified recurring models (FDA, direct sales, leases) without compromising financial stability. Cash remains robust, debt-free, and inventory is positioned to support accelerated 2026 placements.

Most important disclosure this time to filter out signal from all the noise - “Delivered 11,411 FDA treatments to 922 patients during 2025, compared with 1,367 treatments delivered to 264 patients during 2024”

Humphrey Neill

StockTwits for iOS

Sensus Healthcare Inc

 Why is this decline positive for the company’s future?

Because it reflects a strategic transition away from dependency on a single large buyer and toward diversified recurring models (FDA, direct sales, leases) without compromising financial stability. Cash remains robust, debt-free, and inventory is positioned to support accelerated 2026 placements.

Most important disclosure this time to filter out signal from all the noise - “Delivered 11,411 FDA treatments to 922 patients during 2025, compared with 1,367 treatments delivered to 264 patients during 2024”